10 completed, 2 terminated. 4 Phase 2, 4 Phase 4, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 4 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Doxercalciferol: new trials by email Literature Review of Doxercalciferol trials Research Report on Doxercalciferol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 CTAP101 Capsules, Calcitriol, Doxercalciferol - Chronic Kidney Disease, Hyperparathyroidism, Secondary | Phase 3 | Completed | OPKO Health, Inc. | 298 | 2013-04-01 | 2016-09-29 |
| Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients Doxercalciferol, placebo, 25-OH Vitamin D3 - Chronic Kidney Disease, Kidney Transplantation | Phase 4 | Completed | Mariana Markell | 39 | 2008-11-01 | 2019-02-22 |
| Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) CTAP201 Injection, Doxercalciferol - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Completed | OPKO IP Holdings II, Inc. | 24 | 2008-11-01 | 2014-09-29 |
| The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4. cholecalciferol, doxercalciferol, placebo - Chronic Kidney Disease | Phase 4 | Completed | Indiana University | 100 | 2008-07-01 | 2013-03-29 |
| A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis Doxercalciferol, Placebo - Moderate to Severe Chronic Plaque Psoriasis | Phase 2 | Completed | Genzyme, a Sanofi Company | 111 | 2008-04-01 | 2014-05-05 |
| Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients doxercalciferol - Hyperparathyroidism, Secondary | Phase 4 | Terminated | Emory University | 12 | 2008-04-01 | 2015-01-26 |
| How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis doxercalciferol - Hyperparathyroidism, Secondary, Kidney Failure, Chronic | Phase 4 | Completed | Duke University | 24 | 2007-09-01 | 2016-01-22 |
| Doxercalciferol in Recurrent Pediatric Solid Tumors Doxercalciferol - Solid Tumors | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2007-08-01 | 2012-07-31 |
| Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease doxercalciferol, Cholecalciferol - Renal Osteodystrophy | Not applicable | Completed | Indiana University | 55 | 2006-01-01 | 2016-05-02 |
| Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia doxercalciferol - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | University of Wisconsin, Madison | 2002-09-01 | 2019-11-19 | |
| Doxercalciferol Before Surgery in Treating Localized Prostate Cancer doxercalciferol, conventional surgery - Prostate Cancer | Phase 2 | Completed | University of Wisconsin, Madison | 60 | 2001-08-01 | 2019-12-13 |
| Regulation of Bone Formation in Renal Osteodystrophy 1 alpha D2, 1,25 dihydroxy vitamin D3, Sevelamer HCl - Secondary Hyperparathyroidism, Renal Osteodystrophy | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 61 | 2000-11-01 | 2010-01-14 |
Hyperparathyroidism, Secondary (5) · Renal Insufficiency, Chronic (4) · Kidney Failure, Chronic (3) · Chronic Kidney Disease-Mineral and Bone Disorder (2) · Hyperparathyroidism (2) · Kidney Diseases (2) · Parathyroid Diseases (2) · Renal Insufficiency (2) · Leukemia (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms (1)
Indiana University (2) · University of Wisconsin, Madison (2) · Duke University (1) · Emory University (1) · Genzyme, a Sanofi Company (1) · M.D. Anderson Cancer Center (1) · Mariana Markell (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · OPKO Health, Inc. (1) · OPKO IP Holdings II, Inc. (1)
United States (10)
Joel Melnick, MD (2) · George Wilding, MD (1) · Isidro B Salusky, MD (1) · Jula Inrig, MD, MHS (1) · Lynda Szczech, MD (1) · Mariana Markell, MD (1) · Mark B. Juckett, MD (1) · Peter E. Zage, MD, PhD (1) · Sharon M Moe, MD (1) · Sharon Moe, MD (1)
PMID 18203012, PMID 20056760, PMID 40576086
P30CA014520 (2)